Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality rates worldwide [@B1]. Unfortunately, some HCC patients are not eligible for radiofrequency ablation or surgical resections, thus must only rely on chemotherapy. However, the inherent multidrug resistance (MDR) towards chemotherapeutics often impairs the effect of chemotherapy for HCC therefore cannot produce satisfactory clinical outcomes [@B2]. Drug resistance is a multifactorial phenomenon involving many mechanisms, such as T2DM and IR caused by tumorigenesis and inflammation in the liver [@B3]-[@B5]. Our previous studies also validated that IR enhances the tolerance of HCC cells to chemotherapeutic [@B6]-[@B9], indicating that IR contributes to the inherent MDR of HCC. Nevertheless, the key underlying mechanism of the acquisition of resistance to chemotherapeutic drugs still remain largely unexplored.

miRNAs are endogenously expressed small non-coding RNAs with 18-25 nucleotides which play a vital role in the regulation of gene expression at post-transcriptional level [@B10]. Emerging evidences have revealed that miRNAs are important modulators in many signaling pathways involved in tumorigenesis [@B11]. Furthermore, significant variation with miRNA expression were observed in drug tolerant cancer cells in comparison with their parental drug sensitive cancer cells which displays as higher expression of cancer-promoting miRNAs (oncomiRNAs) and lower expression of cancer-inhibiting miRNAs (tumor suppressor miRNAs) [@B12].They might serve as tumor suppressors or oncogenes and constitute ideal targets in exploring anticancer therapeutics [@B13]. miRNAs have been showed as regulators that can promote or impair drug resistance in several cancers including HCC. Kabir TD et al reported that miR-7 could overcome sorafenib resistance by suppressing its target TYRO3 via PI3-Kinase/AKT pathway [@B14]. Xia H etc. declared that miR-216a/217 could activate TGF-β pathway to induce sorafenib resistance [@B15]. Meng W etc. believed that inhibition of the expression of miR-33a-5p could reduce cisplatin sensitivity and increased its drug resistance in HCC [@B16]. Another group identified the role of miR-195 in developing drug resistance in HCC cell line [@B17]. They found that it might improve 5-FU sensitivity by targeting Bcl-w protein to increase cell apoptosis. It was also reported that miR-3129-5p and its target gene Zeb1 endow HCC cells a tolerance to doxorubicin [@B18]. Due to the important role of miRNAs in the development of drug resistance of HCC, it is useful to employed global and systematic analytic techniques to assess the miRNA expression profiles in the drug resistant HCC cells.

Chemoresistance mediated by insulin resistance in HCC have already been validated by our previous studies [@B6]-[@B9], while little was known concerning the role of miRNAs in IR-mediated chemotherapy resistance. Thus, in the current study, comprehensive expression profiling of miRNAs by microarray was performed in insulin-resistant and parental HCC cell lines. Differentially expressed miRNA were identified between these two cell lines with bioinformatics analyses, which may contribute to a better understanding of the potential role of miRNAs in multidrug resistance of the insulin-resistant HCC cells.

Materials and Methods
=====================

Cell culture
------------

Human hepatocellular carcinoma HepG2 cells were purchased from American Type Culture Collection (ATCC HB-8065, Rockville, MD, USA) and cultured in Dulbecco\'s modified eagle medium (DMEM) supplemented with 10% FBS at 37 °C with 5% CO~2~. IR was induced in HepG2 cells according to the method described previously [@B7]. Briefly, cells were incubated in serum-free DMEM for 6 hr to synchronization then treated with insulin at a concentration of 0.5 μM for 72 hr. The resultant cells were named as HepG2/IR cells.

RNA extraction
--------------

Total RNAs from each sample were individually isolated using QIAzol Lysis Reagent and miRNeasy mini kit (Qiagen Inc, Valencia, CA, USA) according to the manufacturers\' instructions. This procedure efficiently recovered all types of RNAs, including miRNAs. RNA quantity and quality were measured using a NanoDrop spectrophotometer (ND-1000; Nanodrop Technologies, Wilmington, DE, USA) and RNA integrity was detected by gel electrophoresis.

Affymetrix GeneChip miRNA Array Hybridization
---------------------------------------------

For analysis with Affymetrix GeneChip miRNA Arrays (Affymetrix, Santa Clara, CA, USA), each sample was prepared with 150 ng of total RNAs. Samples were labeled with the FlashTag Biotin HSR labeling kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer\'s instructions. The RNA sample was mixed into the Poly A Tailing master mix, and FlashTag™ Biotin HSR Ligation was performed by adding FlashTag Biotin HSR Ligation Mix to each of the tailed RNA samples. T4 DNA Ligase was added to each sample for labeling reaction. The hybridization cocktail was then added to each labeled sample, the resultant mix of each sample was applied to an array on the Affymetrix GeneChip miRNA 4.0 Arrays, the probe arrays were washed and stained, then scanned and analyzed using the Affymetrix GeneChip Fluidics Station 450. Differentially expressed miRNAs were identified using fold changes as well as P values calculated by the Student\'s t-test. The thresholds set for up and down regulated miRNAs were a fold change ≥2.0 and P≤0.05.

Bioinformatics analysis
-----------------------

Potential target genes of differentially expressed miRNAs were predicted using DIANA-miRPath online software [@B19], with Micro T threshold set at 0.8 and P-value threshold set at 0.05. The predicted target genes subsequently underwent Gene Ontology (GO) analysis for functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) database analysis to identify the enriched functions and pathways that might be involved. Fisher\'s exact and Chi-square tests were used to determine the significance of the GO and KEGG terms and pathways. Only the KEGG terms with a P-value\<0.01 and GO terms with a P-value\<1E-10 were selected.

miRNA-gene network analyses
---------------------------

To improve the understanding of the associations between the differentially expressed miRNAs and its target genes, miRNA-gene network was constructed according to the regulatory associations between miRNAs and target genes. The associations of the genes and miRNAs were constructed by Cytoscape 3.7.2 software. The output degree was used to measure the regulated effect of miRNAs on genes or effect of genes on miRNAs.

miRNA-GO network analysis
-------------------------

The miRNA-GO network was constructed according to the significantly expressed miRNAs and the results of the GO analysis. The degree of miRNAs indicated the number of GOs which were regulated by the miRNA in the network. In the same way, a higher degree of GO indicated that more miRNAs involved in the GO category. Similarly, a higher degree of miRNA suggested more GO categories related with certain miRNA.

miRNA-KEGG network analysis
---------------------------

A miRNA-KEGG network was constructed according to the specifically regulated miRNAs and the KEGG analysis. The degree of miRNAs indicated the number of KEGG pathways which was regulated by the miRNA in the network. In the same way, a higher degree of KEGG indicated that more miRNAs involved in the KEGG pathway.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
----------------------------------------------------------------------

To validate the authenticity of miRNA expression detected by microarray assay and the crucial predicted target genes of these miRNAs, 14 differentially expressed miRNAs were analyzed by qRT-PCR, including down-regulated miRNAs such: as hsa-miR-134-5p, hsa-miR-5195-3p, hsa-miR-641, hsa-miR-3935 and; up-regulated miRNAs such as hsa-miR-1231 (ID: hsmq-0529), hsa-miR-6726-5p (ID: hsmq-2842), has-miR-3180 (ID: hsmq-1188), sa-miR-3613-5p (ID: hsmq-1112), hsa-miR-6779-5p (ID: hsmq-2840), hsa-miR-7111-5p (ID: hsmq-2216), hsa-miR-6870-5p (ID: hsmq-2604), hsa-miR-6813-5p (ID: hsmq-2845), hsa-miR-4492 (ID: hsmq-1344) and hsa-miR-4505 (ID: hsmq-1358). For this analysis, the miRNAs were detected using the All-in-One™ miRNA qRT-PCR Detection Kit (GeneCopoeia, Rockville, MD, USA) according to the manufacturer\'s instructions. Item ID of each primer is showed before. qPCR was performed using SYBR-Green (Thermo Fisher Scientific, Inc.) reagent according to the manufacturer\'s instructions in the ABI 7300 real-time qPCR system (Thermo Fisher Scientific, Waltham, MA, USA). The relative abundance of each miRNA was calculated by the comparative Ct method (2-ΔΔCt), and the results were assessed by using a t-test.

Statistical analysis of qRT-PCR result
--------------------------------------

All quantitative data were presented as means ± standard deviations. Comparisons between HepG2/IR and it parental cells were performed using the Student\'s t-test. P-values \<0.05 were considered statistically significant. Statistical values were calculated using SPSS software, version 20.0 (IBM Corp, Armonk, NY, USA).

Results
=======

miRNA microarray analysis
-------------------------

To identify the differentially expressed miRNAs between HepG2/IR cells and its parental cells, both cell lines were subjected to the Affymetrix microRNA 4.0 array in triplicate. The results revealed that, of all the 2006 miRNAs screened, 32 miRNAs were dysregulated in HepG2/IR cells compared with its normal control (Table [1](#T1){ref-type="table"}) under the condition of \'fold change\>2 and P\<0.05\'. Among these 32 miRNAs, 27 were up-regulated and 5 were down-regulated. An unsupervised 2D‑cluster analysis was applied for these two cell lines (Fig. [1](#F1){ref-type="fig"}) Volcano plot of significantly expressed miRNAs between HepG2/IR and HepG2 cells were showed in Fig. [2](#F2){ref-type="fig"} and the 32 of them were highlighted.

Target genes and bioinformatics analysis
----------------------------------------

A total of 5,406 genes were predicted as target genes of the identified 32 differentially expressed miRNAs ([Table S1](#SM0){ref-type="supplementary-material"}). To better understand the potential implications of these dysregulated miRNAs, the target genes were subjected to GO analysis to evaluate their potential functions using DIANA-miRPath v3.0 online software (<http://snf-515788.vm.okeanos.grnet.gr/>). In the present study, the top GO terms of the target genes of the dysregulated miRNAs were regulation of cellular nitrogen compound metabolic process, biosynthetic process, cellular protein modification process (BP); cellular component, protein complex, cytosol (CC); ion binding, transcription coactivator activity, molecular function, nucleic acid binding transcription factor activity (MF) (Fig. [3](#F3){ref-type="fig"}, [Table S2](#SM0){ref-type="supplementary-material"}).

The target genes were also subjected to KEGG pathway enrichment analysis using DIANA-miRPath v3.0 online software (<http://snf-515788.vm.okeanos.grnet.gr/>) to determine the canonical pathways controlled by the identified miRNAs. Other types of O-glycan biosynthesis, proteoglycans in cancer, adrenergic signaling in cardiomyocytes, estrogen signaling pathway, cell adhesion molecules, glycosphingolipid biosynthesis, glycosaminoglycan biosynthesis, and ErbB signaling pathway were the most active pathways that the target genes of the differentially expressed miRNAs may be involved. (Fig. [4](#F4){ref-type="fig"}, [Table S3](#SM0){ref-type="supplementary-material"}).

miRNA-gene-network analyses
---------------------------

A miRNA-gene network was constructed according to the results of the GO and KEGG pathway analyses. The core miRNAs of the interaction network include miR-6870-5p, miR-7111-5p, miR-4505, miR-4492 and miR-641 (Table [2](#T2){ref-type="table"}). The network also revealed that Kinase suppressor of Ras 2 (KSR2), Ras/Rap GTPase-activating protein SynGAP (SYNGAP1), Glutamate receptor ionotropic (GRIN2B), G protein-activated inward rectifier potassium channel 2 (KCNJ6), and Complexin-2 (CPLX2) were the most crucial target genes (Table [3](#T3){ref-type="table"}, [Table S1](#SM0){ref-type="supplementary-material"}). The associations of miRNAs with genes were shown in Fig. [5](#F5){ref-type="fig"}.

miRNA-GO network analysis
-------------------------

The *miRNA-*GO network analysis was favourable for determining regulatory associations between the key miRNAs and hub GO. In this network, miR-4492, miR-641 and miR-6779-5p, which contributed more than the other specifically expressed miRNAs exhibit 114, 114 and 113 GO functions, respectively (Table [4](#T4){ref-type="table"}, [Table S4](#SM0){ref-type="supplementary-material"}). The most significantly regulated functional clusters of total categories were cellular nitrogen compound metabolic process, biosynthetic process, biological process and catabolic process (Table [5](#T5){ref-type="table"}). The significantly complicated categories associations of miRNAs with degree more than 25 were shown in Fig. [6](#F6){ref-type="fig"}.

miRNA-KEGG network analysis
---------------------------

The network analysis was also employed to determine regulatory associations between the key miRNAs and hub KEGG pathways. In this network, miR-4492, miR-5193-3p and miR-641, which contributed more than other specifically expressed miRNAs exhibited 45, 44 and 44 KEGG pathways respectively (Table [6](#T6){ref-type="table"}, [Table S5](#SM0){ref-type="supplementary-material"}). The most significantly KEGG pathway were MAPK signaling pathway, Ras signaling pathway, endocytosis and Rap1 signaling pathway, which involved in cell proliferation, growth, and differentiation (Table [7](#T7){ref-type="table"}). The significantly complicated pathway associations of miRNAs with degree more than 30 are shown in Fig. [7](#F7){ref-type="fig"}.

Validation of miRNA array data
------------------------------

Based on their expression levels and fold changes, 4 downregulated miRNAs (miR-134-5p, miR-5195-3p, miR-641, miR-3935) and 10 upregulated miRNAs (miR-1231, miR-6726-5p, miR-3613-5p, miR-6779-5p, miR-7111-5p, miR-6870-5p, miR-6813-5p, miR-4492, miR-4505, miR-3180) were selected for validation by qRT-PCR. The results revealed a significant difference of the expression level of miR-4492, miR-3180, miR-134-5p, miR-5195-3p, miR-641 between the IR cells and control cells, which was in a manner consistent with the data obtained from microarray analysis (P\<0.05) (Fig. [8](#F8){ref-type="fig"}). GO enrichment analysis revealed that these validated miRNAs were significantly enriched in biosynthetic process, cellular protein modification process, gene expression, small molecule metabolic process, catabolic process, cellular component assembly, post-translational protein modification ([Table S4](#SM0){ref-type="supplementary-material"}). The pathways were also significantly enriched in the KEGG analysis, and the most involved were cancer-related pathways, including the: Ras signaling pathway, Hippo signaling pathway, ErbB signaling pathway, other types of O-glycan biosynthesis, proteoglycans in cancer and cell adhesion molecules (CAMs) ([Table S5](#SM0){ref-type="supplementary-material"}).

Discussion
==========

As the main anabolic hormone of the body, insulin regulates the metabolism of nutrients and promotes absorption of glucose from the blood into the cells. IR is the status when cells in the body, especially cells in the liver, fat and muscles don\'t respond well to insulin, and correspondingly the uptake and utilization of glucose decreases. At the whole organism level, IR will cause an impaired effect of insulin with lowering blood glucose, which may develop T2DM. To compensate for low blood glucose, the pancreas compensatory secretes excessive insulin to maintain blood sugar stability and to help glucose entering the cells. This excessive secretion leads to hyperinsulinemia in the body, which in turn activates hepatic lipogenesis and increased secretion of VLDL (hyperlipidemia) [@B20].

Nonalcoholic fatty liver disease (NAFLD), as one of the most common liver disorders worldwide [@B21], had already been reported to have tight association with IR. Although NAFLD includes a disease spectrum, ranging from simple steatosis, liver cirrhosis to hepatocellular carcinoma (HCC) etc. [@B22],[@B23] and the overall occurrence from NAFLD to HCC remains a rare complication [@B24],[@B25]. IR had been reported to be associated with increased risk of several cancers, including HCC [@B26],[@B27]. It had not only been related to tumorigenesis, but also been correlated to the poor prognosis of cancer patients [@B3]-[@B5]. Our previous studies also proved that IR could increase the invasiveness and MDR in the HCC cell line [@B6]-[@B9]. However, the molecular mechanism of therapeutic resistance caused by IR still remains unclear.

Our present study demonstrated that 27 miRNAs were consistently upregulated and 5 miRNAs were downregulated in the HepG2/IR cells upon triplicate tests. qRT-PCR was employed to verify the expression data of 14 differentially expressed miRNAs, which showed that the expression of 5 miRNAs were in consistent with the microarray data. The outcome of qRT-PCR validated that our result of microarray screening was reliable. Among these validated miRNAs, some had already been reported to be correlated with cancer. For instance, miR-134-5p had been reported as a tumor suppressing miRNA involving in several cancers. The anti-tumor mechanisms of miR-134-5p as the potential target of various lncRNAs which function as oncogene and it can also inhibit the expression of tumor suppressor genes by directly binding to the 3\'UTR region. It was confirmed that impairing the expression of miR-134-5p can promote cell proliferation, inhibit cell apoptosis, accelerate cell migration, invasion, and induce EMT and moreover contribute to multidrug resistance such as cisplatin (targeting MBTD1), 5-FU (targeting KRAS) and paclitaxel (targeting TAB1) in several carcinoma cells including non-small-cell lung, gastric, nasopharyngeal, ovarian cancers and osteosarcoma [@B32]-[@B35],[@B55],[@B56]. Another microRNA reported was miR-641 which has been proved as a tumor suppressor; inhibiting proliferation, migration and invasion, as well as inducing apoptosis in lung cancer, cervical cancer and glioblastoma [@B36]-[@B38]. It was also confirmed that miR-641 contributes to erlotinib resistance in non-small-cell lung cancer by targeting NF1 and regulating ERK signaling [@B39]. However, little was known about the role of miR-641 in HCC. The only report about miR-641 and drug metabolism is that it acts as a direct post-transcriptional regulatory factor of CYP3A4, which is a member of the cytochrome P450 superfamily. As we all know, the cytochrome P450 proteins are monooxygenases in the hepatocytes that catalyze many reactions involved in drug metabolism, the enzyme also metabolizes some steroids and carcinogens as well [@B40]. Until now, the functions especially in tumorigenesis and drug resistance of other validated miRNAs such as miR-3180, miR-6726-5p, miR-7111-5p etc. have remained unclear. Our previous study has reported that insulin resistant HCC cells obtain ability of multidrug resistance such as cisplatin, 5-FU, vincristine, mitomycin [@B7]. In accordance with the researches mentioned above, miR-134-5p and miR-641 were down-regulated in insulin resistant HCC cells, thus suggesting that these known or unknown miRNAs might play a critical role in multidrug resistance of insulin resistant HCC cells especially miR-134-5p and miR-641. Further functional experiments will be conducted in our following study.

miRNA mainly performs its regulatory function through its targets. Functions of these predicted target genes significantly enriched in the processes related with metabolic, biosynthetic, transcriptional and protein modification etc., biological regulatory mechanisms were integrated in several main KEGG pathways, most of which are cancer-related pathways, such as Ras signaling pathway, Hippo signaling pathway, ErbB signaling pathway, other types of O-glycan biosynthesis etc. These pathways regulate cell proliferation, adhesion, migration, differentiation, evasion and angiogenesis [@B28]-[@B31]. The most significant KEGG pathway was other types of O-glycan biosynthesis. It was believed that the aberrant O-glycan of cell surface influence the adhesion of cancer cells to the endothelium, promoting tumor migration, invasion and favoring cancer cells epithelial-to-mesenchymal transition (EMT). During malignancy progression, tumor cells prevalently stimulate expression of O-glycans that are normally present on embryonic tissues, but not on well-differentiated adult tissues [@B31],[@B41],[@B42]. This indicates that these dysregulated miRNAs and their target genes may be involving in the tumorigenesis, drug resistance and tumor progression of the insulin resistant HCC cell line.

We also constructed a network which connected the differentially expressed miRNAs to their target genes, also to GO and KEGG enrichment. The network revealed the biological functions and contributed to better understanding of the role of dysregulated miRNAs. In these networks, certain miRNAs functioned as network hubs, such as miR-641, miR-6870-5p, miR-7111-5p, miR-4505, miR-4492, and miR-5195-3p. Among these miRNAs, miR-641 was one of the most active miRNAs in the network which targeting 52 genes, 114 GO terms and 44 KEGG pathways. In accord with previous reports, miR-641 was confirmed down-regulated in our present study, suggesting that it might be related with impaired drug sensitivity, migration and adhesion in insulin resistant HepG2 cells. Additional studies are required to elucidate the detailed role of miR-641 in insulin resistant HCC.

The miRNA networks analysis also revealed a range of hub genes (such as KSR2, SYNGAP1), crucial KEGG pathways (Ras signaling pathway, MAPK signaling pathway), and crucial GO (Cellular nitrogen compound metabolic process, Biosynthetic process, Biological process) and most of which were involved in tumorigenesis, drug resistance and poor prognosis of cancer patients [@B43]-[@B48]. Kinase Suppressor of Ras 2 (KSR2) is a molecular scaffold that regulate the intensity and duration of the Ras/Raf/MEK/ERK/MAPK kinase cascade to facilitate energy consumption and expenditure [@B49],[@B50]. Deletion of KSR2 leads to impair the oxidation of fatty acids and increase their storage as triglycerides, reduced basal metabolic rate thus contributing to obesity and insulin resistance [@B49],[@B51]. KSR2 was also reported as an activator to stimulate tumor cell transformation [@B45]. Ojha R et al declared that it interacts with the endoplasmic reticulum (ER) stress chaperone (GRP78) and facilitated ER translocation which drove therapy resistance in BRAF-Mutant melanoma [@B46]. Our present study revealed that as a predicted target gene KSR2 was regulated by eight miRNAs including 7 up-regulated miRNAs (miR-4492, miR-4505, miR-6132, miR-6779-5p, miR-6780b-5p, miR-6870-5p, miR-7111-5p) and 1 down-regulated miRNA (miR-641). It was involved in many GO categories such as cellular protein modification process, cellular_component, cytosol, ion binding, molecular_function, cellular protein modification process, and participated in Ras signaling KEGG pathway. In our previous study [@B6]-[@B8], we found that insulin resistance contributes to multidrug resistance in HCC cells via activation of the ER stress, suggesting that KSR2 may be involved in therapy resistance in insulin resistant HCC. The expression of KSR2 and its relationship with correlated miRNAs need to be further validated.

The cytosolic protein SYNGAP1/RASA5 (SYNaptic GTPase Activating Protein 1) [@B48],[@B52] encoded by SYNGAP1 gene was reported as a Ras signaling suppressor comprised in RASA subfamily (Ras GAPs) [@B53]. It was known that Ras GAPs can inactivate RAS signaling and inhibit oncogenic transformation initiated by RAS. Suppression of Ras GAPs may constitute an additional mechanism whereby aberrant *Ras* activation promotes tumorigenesis [@B47],[@B54]. Li L et al [@B48] declared that expression of SYNGAP1/RASA5 inhibited tumor cell migration/invasion and growth in mouse model, functioning as a tumor suppressor. Conversely, knockdown of SYNGAP1/RASA5 enhanced Ras signaling to promote tumor cell growth. SYNGAP1/RASA5 also inhibited EMT through regulating actin reorganization. Thus, epigenetic inactivation of SYNGAP1/RASA5 contributing to hyperactive RAS signaling is involved in Ras-driven human oncogenesis. In our current study, SYNGAP1 was predicted being targeted only by up-regulated miRNAs including miR-4492, miR-3180, miR-4505, miR-6085, miR-6795-5p, miR-6805-5p, miR-6870-5p miR-7111-5p. It was involved in two GO categories (cellular_component and molecular_function) and participated in Ras signaling pathway. The results suggested that SYNGAP1 might be reduced expression in insulin resistant HepG2 cells. As we known, Ras signaling pathway is often deregulated in tumors through inactivation of Ras inhibitors, SYNGAP1 acts as a tumor suppressor negatively regulated the Ras signaling pathway in cancer. Decreasing expression of SYNGAP1 indicated the enhanced migration, invasion and multidrug resistance in the insulin resistant HCC. Further study should be addressed to validate the expression, regulatory miRNAs, and function of SYNGAP1 in insulin resistant HCC.

In conclusion, our study compared the miRNA expression profile in the insulin resistant HCC cells with its parental cells and identified the differentially expressed miRNAs, which provides information for further understanding of the molecular mechanisms of insulin resistance HCC cells in tumor progression and drug resistance.
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![Heatmap of the microarray hybridization result showed the differentially expressed miRNAs between HepG2/IR cells and its parental cells (HepG2 cells). Total RNA was extracted from both of two cell lines, miRNAs microarrays were performed as described in Materials and Methods, both cell lines were tested in triplicate.](ijmsv17p0664g001){#F1}

![**Volcano plot of differentially expressed miRNA between HepG2/IR and HepG2 cells.** The x-axis shows the Log2 fold-change in miRNA expression and y-axis shows the -Log10 of the p-value from HepG2/IR versus HepG2 cells. Labelled miRNAs have Log2 fold change greater than 1SD from mean.](ijmsv17p0664g002){#F2}

![**Significantly changed GO categories of predicted target genes of deregulated miRNAs between HepG2/IR and HepG2 cells.** The y-axis shows GO category and the x-axis shows -lg*P*. The larger -lg*P* indicated a smaller *P* value. -lg*P* represent the negative logarithm of the *P* value. Blue bars indicate biological process (BP), red bars indicate cellular component (CC) and yellow bars indicate molecular function (MF).](ijmsv17p0664g003){#F3}

![**Significantly changed KEGG pathways of predicted target genes of deregulated miRNAs between HepG2/IR and HepG2 cells.** The y-axis shows KEGG category and the x-axis shows -lg*P*. The larger -lg*P* indicated a smaller *P* value. -lg*P* represent the negative logarithm of the *P* value.](ijmsv17p0664g004){#F4}

![**miRNA-gene network showing the interactions between key miRNAs and the predicted hub genes.** The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub target genes (purple nodes denote crucial and hub target genes with degree \>4).](ijmsv17p0664g005){#F5}

![**miRNA-GO network showing the interactions between key miRNAs and the hub GO.** The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub GO with degree\>25 (purple nodes denote tumor related hub GO).](ijmsv17p0664g006){#F6}

![**miRNA-KEGG network showing the interactions between key miRNAs and the hub KEGG pathway.** The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub KEGG pathway with degree\>30 (purple nodes denote tumor related hub KEGG).](ijmsv17p0664g007){#F7}

![Validation of the microarray results by qRT-PCR. Expression level of the dysregulated miRNAs were shown in the figure. All miRNAs exhibited statistically significant changes in the HepG2/IR cells compared with its parental cells. Relative expression levels were calculated by 2^-ΔΔCt^ method after the (cycle threshold) Ct value (power amplification knee point) was obtained. Experiments were repeated three times with similar results, and the results are presented as mean±SD of triplicate experiments. \*P\<0.05, \*\* P\<0.01.](ijmsv17p0664g008){#F8}

###### 

Differentially expressed microRNAs (miRNAs) between HepG2/IR cells and its parental control (p\<0.05, Fold change\>2)

  miRNA              p-value      Fold Change   Type of regulation
  ------------------ ------------ ------------- --------------------
  hsa-miR-3613-5p    0.0242590    6.28          Up
  hsa-miR-6813-5p    0.0123839    6.12          Up
  hsa-miR-6132       0.0099436    4.05          Up
  hsa-miR-4492       0.0160402    3.59          Up
  hsa-miR-3937       0.0468370    3.36          Up
  hsa-miR-7112-5p    0.0283560    3.31          Up
  hsa-miR-6795-5p    0.0137803    3.28          Up
  hsa-miR-6726-5p    0.0052162    3.11          Up
  hsa-miR-6848-5p    0.0044207    3.07          Up
  hsa-miR-6870-5p    0.0001978    3.01          Up
  hsa-miR-7111-5p    0.0247380    2.94          Up
  hsa-miR-6780b-5p   0.0398410    2.90          Up
  hsa-miR-6782-5p    0.0193971    2.82          Up
  hsa-miR-3180       0.0482000    2.73          Up
  hsa-miR-4467       0.0296810    2.72          Up
  hsa-miR-6805-5p    0.0174751    2.66          Up
  hsa-miR-6846-5p    0.0231760    2.54          Up
  hsa-miR-4706       0.0456770    2.48          Up
  hsa-miR-4505       0.0307830    2.38          Up
  hsa-miR-8072       0.0176760    2.37          Up
  hsa-miR-6085       0.0333000    2.28          Up
  hsa-miR-4649-5p    0.0200810    2.25          Up
  hsa-miR-6757-5p    0.0040993    2.23          Up
  hsa-miR-6779-5p    0.0167355    2.18          Up
  hsa-miR-3621       0.0468600    2.13          Up
  hsa-miR-1231       0.033018     2.08          Up
  hsa-miR-4508       0.0143212    2.04          Up
  hsa-miR-641        0.027156     -2.23         Down
  hsa-miR-4793-5p    0.0133985    -2.27         Down
  hsa-miR-134-5p     0.040759     -2.95         Down
  hsa-miR-5195-3p    0.00055787   -3.30         Down
  hsa-miR-3935       0.030403     -3.55         Down

###### 

Crucial microRNAs (miRNAs) in the miRNA-target network (degree \>3)

  miRNA              Degree
  ------------------ --------
  hsa-miR-6870-5p    87
  hsa-miR-7111-5p    67
  hsa-miR-4505       66
  hsa-miR-4492       57
  hsa-miR-641        52
  hsa-miR-6780b-5p   50
  hsa-miR-5195-3p    48
  hsa-miR-6846-5p    46
  hsa-miR-6848-5p    45
  hsa-miR-6779-5p    41
  hsa-miR-6795-5p    27
  hsa-miR-6132       26
  hsa-miR-134-5p     22
  hsa-miR-3613-5p    19
  hsa-miR-1231       18
  hsa-miR-4793-5p    17
  hsa-miR-6085       17
  hsa-miR-6813-5p    16
  hsa-miR-6782-5p    14
  hsa-miR-3935       13
  hsa-miR-6757-5p    13
  hsa-miR-6726-5p    8
  hsa-miR-6805-5p    8
  hsa-miR-3180       4

###### 

Crucial and hub target genes in the miRNA-target network (degree \>4)

  Crucial Target Gene   Description                                                          Degree
  --------------------- -------------------------------------------------------------------- --------
  CPLX2                 Complexin-2                                                          8
  GRIN2B                Glutamate receptor ionotropic, NMDA 2B                               8
  KCNJ6                 G protein-activated inward rectifier potassium channel 2             8
  KSR2                  Kinase suppressor of Ras 2                                           8
  SYNGAP1               Ras/Rap GTPase-activating protein SynGAP                             8
  THRA                  Thyroid hormone receptor alpha                                       8
  AGAP2                 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2   7
  PTCH1                 Protein patched homolog 1                                            7
  SEMA4G                Semaphorin-4G                                                        7
  VAMP2                 Vesicle-associated membrane protein 2                                7
  CDK6                  Cyclin-dependent kinase 6                                            6
  CRTC2                 CREB-regulated transcription coactivator 2                           6
  PAK6                  Serine/threonine-protein kinase PAK 6                                6
  PRKCA                 Protein kinase C alpha type                                          6
  ATP2B2                Plasma membrane calcium-transporting ATPase 2                        5
  CACNB3                Voltage-dependent L-type calcium channel subunit beta-3              5
  FLNB                  Filamin-B                                                            5
  PPP1R12B              Protein phosphatase 1 regulatory subunit 12B                         5
  SLC8A1                Sodium/calcium exchanger 1                                           5
  VPS37D                Vacuolar protein sorting-associated protein 37D                      5

###### 

Crucial miRNAs in the miRNA-GO network (degree \>10)

  miRNA              Degree
  ------------------ --------
  hsa-miR-4492       114
  hsa-miR-641        114
  hsa-miR-6779-5p    113
  hsa-miR-6870-5p    113
  hsa-miR-7111-5p    110
  hsa-miR-3613-5p    109
  hsa-miR-6780b-5p   108
  hsa-miR-4505       106
  hsa-miR-6846-5p    105
  hsa-miR-6795-5p    104
  hsa-miR-134-5p     101
  hsa-miR-4793-5p    101
  hsa-miR-6848-5p    101
  hsa-miR-5195-3p    100
  hsa-miR-1231       97
  hsa-miR-6132       97
  hsa-miR-6757-5p    97
  hsa-miR-6813-5p    96
  hsa-miR-6782-5p    92
  hsa-miR-6085       91
  hsa-miR-3935       81
  hsa-miR-3937       74
  hsa-miR-6805-5p    67
  hsa-miR-6726-5p    63
  hsa-miR-3180       59
  hsa-miR-4649-5p    58
  hsa-miR-4508       33
  hsa-miR-4706       33
  hsa-miR-7112-5p    33
  hsa-miR-4467       29
  hsa-miR-3621       20
  hsa-miR-8072       16

###### 

Crucial GO category in the microRNA-GO network (degree \>20)

  GO ID   GO (name)    Degree                                                         P value   
  ------- ------------ -------------------------------------------------------------- --------- -----------
  BP      GO:0034641   cellular nitrogen compound metabolic process                   32        1.93E-70
  BP      GO:0009058   biosynthetic process                                           32        8.87E-43
  BP      GO:0008150   biological_process                                             32        2.79E-06
  BP      GO:0009056   catabolic process                                              31        2.45E-18
  BP      GO:0022607   cellular component assembly                                    31        4.15E-17
  BP      GO:0006351   transcription, DNA-templated                                   31        0.0449519
  BP      GO:0006464   cellular protein modification process                          30        5.95E-38
  BP      GO:0044281   small molecule metabolic process                               30        2.21E-23
  BP      GO:0006950   response to stress                                             30        3.49E-09
  BP      GO:0034655   nucleobase-containing compound catabolic process               29        1.98E-11
  BP      GO:0065003   macromolecular complex assembly                                29        1.19E-10
  BP      GO:0006461   protein complex assembly                                       29        3.48E-07
  BP      GO:0016192   vesicle-mediated transport                                     29        0.0433165
  BP      GO:0002376   immune system process                                          28        2.04E-06
  BP      GO:0008219   cell death                                                     28        2.97E-06
  BP      GO:0006259   DNA metabolic process                                          28        0.0073611
  BP      GO:0010467   gene expression                                                27        3.60E-35
  BP      GO:0044403   symbiosis, encompassing mutualism through parasitism           27        1.57E-26
  BP      GO:0044267   cellular protein metabolic process                             27        8.96E-20
  BP      GO:0048011   neurotrophin TRK receptor signaling pathway                    26        6.94E-37
  BP      GO:0016032   viral process                                                  26        2.41E-26
  BP      GO:0043687   post-translational protein modification                        26        4.23E-17
  BP      GO:0061024   membrane organization                                          26        5.18E-12
  BP      GO:0007267   cell-cell signaling                                            26        1.13E-09
  BP      GO:0051056   regulation of small GTPase mediated signal transduction        26        1.07E-05
  BP      GO:0006367   transcription initiation from RNA polymerase II promoter       26        5.57E-05
  BP      GO:0042592   homeostatic process                                            26        0.0079643
  BP      GO:0030198   extracellular matrix organization                              26        0.0361203
  BP      GO:0007596   blood coagulation                                              25        6.77E-18
  BP      GO:0007268   synaptic transmission                                          25        5.55E-14
  BP      GO:0016070   RNA metabolic process                                          25        3.88E-06
  BP      GO:0045087   innate immune response                                         25        0.0002734
  BP      GO:0048870   cell motility                                                  25        0.000421
  BP      GO:0007010   cytoskeleton organization                                      25        0.0095913
  BP      GO:0016071   mRNA metabolic process                                         24        3.49E-09
  BP      GO:0007411   axon guidance                                                  24        0.0001162
  BP      GO:0097190   apoptotic signaling pathway                                    24        0.0084989
  BP      GO:0007399   nervous system development                                     24        0.0092641
  BP      GO:0006790   sulfur compound metabolic process                              24        0.0392062
  BP      GO:0038095   Fc-epsilon receptor signaling pathway                          23        1.46E-26
  BP      GO:0007173   epidermal growth factor receptor signaling pathway             23        1.72E-14
  BP      GO:0030203   glycosaminoglycan metabolic process                            23        2.21E-10
  BP      GO:0000278   mitotic cell cycle                                             23        2.73E-08
  BP      GO:0030168   platelet activation                                            23        3.73E-07
  BP      GO:0008286   insulin receptor signaling pathway                             23        2.61E-06
  BP      GO:0019221   cytokine-mediated signaling pathway                            23        0.0327518
  BP      GO:0008543   fibroblast growth factor receptor signaling pathway            22        3.49E-09
  BP      GO:0034142   toll-like receptor 4 signaling pathway                         22        2.23E-08
  BP      GO:0034330   cell junction organization                                     22        3.30E-06
  BP      GO:0006325   chromatin organization                                         22        0.0046663
  BP      GO:0022617   extracellular matrix disassembly                               22        0.0138599
  BP      GO:0006091   generation of precursor metabolites and energy                 22        0.0460089
  BP      GO:0038096   Fc-gamma receptor signaling pathway involved in phagocytosis   21        1.01E-13
  BP      GO:0034162   toll-like receptor 9 signaling pathway                         21        1.01E-09
  BP      GO:0002224   toll-like receptor signaling pathway                           21        6.22E-07
  BP      GO:0048015   phosphatidylinositol-mediated signaling                        21        1.05E-06
  BP      GO:0006928   cellular component movement                                    21        9.77E-05
  BP      GO:0006644   phospholipid metabolic process                                 21        0.0001544
  BP      GO:0000086   G2/M transition of mitotic cell cycle                          21        0.0024742
  CC      GO:0005575   cellular_component                                             32        1.93E-22
  CC      GO:0043234   protein complex                                                30        5.11E-20
  CC      GO:0005829   cytosol                                                        30        1.17E-15
  CC      GO:0005654   nucleoplasm                                                    30        1.03E-13
  CC      GO:0005815   microtubule organizing center                                  26        0.0031329
  MF      GO:0043167   ion binding                                                    32        5.38E-85
  MF      GO:0003674   molecular_function                                             32        9.58E-29
  MF      GO:0001071   nucleic acid binding transcription factor activity             30        1.33E-22
  MF      GO:0000988   protein binding transcription factor activity                  27        3.47E-21
  MF      GO:0019899   enzyme binding                                                 27        1.21E-20
  MF      GO:0008092   cytoskeletal protein binding                                   28        1.25E-16
  MF      GO:0030234   enzyme regulator activity                                      29        2.03E-10
  MF      GO:0022857   transmembrane transporter activity                             28        9.52E-05
  MF      GO:0030674   protein binding, bridging                                      23        0.0343038

###### 

Crucial miRNAs in the miRNA-KEGG network (degree \>10)

  miRNA              Degree
  ------------------ --------
  hsa-miR-4492       45
  hsa-miR-5195-3p    44
  hsa-miR-641        44
  hsa-miR-4505       43
  hsa-miR-6870-5p    43
  hsa-miR-6848-5p    42
  hsa-miR-6779-5p    41
  hsa-miR-134-5p     39
  hsa-miR-6780b-5p   39
  hsa-miR-6795-5p    39
  hsa-miR-7111-5p    39
  hsa-miR-1231       38
  hsa-miR-6846-5p    38
  hsa-miR-4793-5p    37
  hsa-miR-6757-5p    37
  hsa-miR-3613-5p    34
  hsa-miR-3935       32
  hsa-miR-6813-5p    32
  hsa-miR-6782-5p    28
  hsa-miR-6805-5p    28
  hsa-miR-6132       27
  hsa-miR-6085       21
  hsa-miR-3937       15
  hsa-miR-3180       14

###### 

Crucial KEGGs in the miRNA-KEGG network (degree \>30)

  KEGG ID    KEGG_Term                                                  Degree   P value
  ---------- ---------------------------------------------------------- -------- -------------
  hsa04010   MAPK signaling pathway                                     97       0.008968411
  hsa04014   Ras signaling pathway                                      87       0.003145657
  hsa04144   Endocytosis                                                85       0.004307909
  hsa04015   Rap1 signaling pathway                                     84       0.0045072
  hsa04024   cAMP signaling pathway                                     76       0.035393834
  hsa05205   Proteoglycans in cancer                                    73       0.000299322
  hsa04921   Oxytocin signaling pathway                                 68       0.002905436
  hsa04261   Adrenergic signaling in cardiomyocytes                     65       0.000450147
  hsa04390   Hippo signaling pathway                                    61       0.003145657
  hsa04360   Axon guidance                                              56       0.008176788
  hsa04550   Signaling pathways regulating pluripotency of stem cells   56       0.006210047
  hsa04514   Cell adhesion molecules (CAMs)                             56       0.001916405
  hsa04728   Dopaminergic synapse                                       54       0.0194252
  hsa04152   AMPK signaling pathway                                     53       0.00777182
  hsa04611   Platelet activation                                        51       0.017005802
  hsa04919   Thyroid hormone signaling pathway                          49       0.035095754
  hsa04724   Glutamatergic synapse                                      48       0.003145657
  hsa04668   TNF signaling pathway                                      44       0.031542367
  hsa04915   Estrogen signaling pathway                                 42       0.001916405
  hsa04723   Retrograde endocannabinoid signaling                       41       0.01974073
  hsa04750   Inflammatory mediator regulation of TRP channels           41       0.01974073
  hsa04670   Leukocyte transendothelial migration                       40       0.044378808
  hsa04012   ErbB signaling pathway                                     40       0.002905436
  hsa04666   Fc gamma R-mediated phagocytosis                           39       0.034514602
  hsa05414   Dilated cardiomyopathy                                     35       0.044378808
  hsa04540   Gap junction                                               34       0.029084915
  hsa04720   Long-term potentiation                                     32       0.0110171
  hsa04350   TGF-beta signaling pathway                                 31       0.0045072
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